ELASMOGEN, a drug development business spun out of the University of Aberdeen and global biopharma group Amgen have signed a research agreement with Canada’s Feldan Therapeutics.
Using a type of cell that is naturally occurring in sharks, Elasmogen is developing a drug that could help save the sight of patients with inflammatory eye diseases.
The agreement will see the firms combine their technologies to develop drugs based on genetically-engineered proteins, called biologics.
Most biologics can only act on molecules on the surface of cells, which means they are unable to interact with deoxyribonucleic acid (DNA) and certain other proteins which play a key role in disease but only exist inside the cell.
Elasmogen specialises in the development of soloMERs, which are a type of biologics that help treat auto-inflammatory diseases and can be used in ophthalmology, oncology and intracellular delivery.
The collaboration combines Elasmogen’s technology with the capabilities of Feldan’s Shuttle platform, which enables the highly efficient introduction of foreign proteins into cells.
Calling the agreement an “exciting opportunity”, François-Thomas Michaud, chief executive of Feldan Therapeutics, said: “Intracellular delivery and binding of biologics can bridge the gap between small molecules and biologics.”
“The expertise provided by Amgen will significantly accelerate the development of this potential new class of therapeutics,” said Caroline Barelle, CEO, Elasmogen.
Meanwhile, Dundee-based Exscientia, which works in the field of artificial intelligence (AI)-driven drug discovery, has agreed a strategic research collaboration, and licence option agreement with global pharma company Sanofi in the high-interest area of metabolic disease.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here